Clinical trial · Observational
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
NCT01567046CI-TRIAL-00022207completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research trial studies genes in tissue samples from younger and adolescent patients with soft tissue sarcomas. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer
Conditions
Conditions (15)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Childhood Alveolar Soft-part Sarcoma | Childhood Alveolar Soft Part Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Angiosarcoma | Childhood Angiosarcoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Desmoplastic Small Round Cell Tumor | Childhood Desmoplastic Small Round Cell Tumor | ONTOLOGY_EXACT | 0.98 |
| Childhood Epithelioid Sarcoma | Childhood Epithelioid Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Fibrosarcoma | Childhood Fibrosarcoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Leiomyosarcoma | Childhood Leiomyosarcoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Liposarcoma | Childhood Liposarcoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Malignant Mesenchymoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Correlative studies
- description
- Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.
- interventionNames
- Other: laboratory biomarker analysis
Primary outcomes (2)
- measure
- Frequency of individual mutated genes in patients with NRSTS
- timeFrame
- Up to 1 month
- measure
- Genetic changes that are most common and likely to have the greatest therapeutic impact
- timeFrame
- Up to 1 month
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria:
* Archived non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor-derived DNA
* Synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), soft tissue sarcoma not otherwise specified (NOS), or other less common pediatric NRSTS
* Formalin-fixed, paraffin-embedded (FFPE) tissue from patients enrolled on:
* COG-D9902 Soft Tissue Sarcoma (STS) Biology and Banking Protocol
* COG-ARST0332 A Risk-Based Treatment for Pediatric NRSTS Study
* See Disease CharacteristicsReferences
Publications (0)
Data not yet available
No reference posted for this study.